よし兄 Yoshi

呼吸器内科　respiratorymedicine

[よし兄 Yoshi @aminfield]

https://t.co/ZZfG3i4yqB

[よし兄 Yoshi @aminfield]

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer - Lung Cancer https://t.co/taFPXkbjOn

[よし兄 Yoshi @aminfield]

https://t.co/uVZEYovELX

[よし兄 Yoshi @aminfield]

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies | American Society of Clinical Oncology Educational Book https://t.co/q0DUbJRHjm

[よし兄 Yoshi @aminfield]

Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts: Cancer Cell https://t.co/4Dvvr3dHsS

[よし兄 Yoshi @aminfield]

Outcomes and Treatments of Patients With Non–Small Cell Lung Cancer Who Received Pembrolizumab https://t.co/FTxVsAdKob

[よし兄 Yoshi @aminfield]

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer https://t.co/Oau3UyIaxR

[よし兄 Yoshi @aminfield]

Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade https://t.co/rcY1Wf6Ovm

[よし兄 Yoshi @aminfield]

A Roadmap to Precision Immunotherapy for Early-Stage Non–Small Cell Lung Cancer https://t.co/I7DlJ5bQgJ

[よし兄 Yoshi @aminfield]

EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway https://t.co/cMsQ7H5uOJ

[よし兄 Yoshi @aminfield]

Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival https://t.co/8SJwG2kuJi

[よし兄 Yoshi @aminfield]

Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay - Journal of Thoracic Oncology https://t.co/Mf5hj7vbtK

[よし兄 Yoshi @aminfield]

https://t.co/ej3c0G5bjz

[よし兄 Yoshi @aminfield]

Amivantamab induces immune-mediated cytotoxicity in mesothelioma via EGFR and MET engagement - Journal of Thoracic Oncology https://t.co/0axg7Vbnf3

[よし兄 Yoshi @aminfield]

https://t.co/fHyM1KtnNk

[よし兄 Yoshi @aminfield]

Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial - Journal of Thoracic Oncology https://t.co/I5s8evAEoE

[よし兄 Yoshi @aminfield]

Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay - Journal of Thoracic Oncology https://t.co/Mf5hj7vbtK

[よし兄 Yoshi @aminfield]

Combination of Radiotherapy and Immunotherapy in Advanced Non–Small Cell Lung Cancer https://t.co/ZASa0vZAhe

[よし兄 Yoshi @aminfield]

Tumor cells metabolically resist immune-checkpoint therapy by macrophage efferocytosis-mediated fatty acid recycling: Cancer Cell https://t.co/Tee5ylfScf

[よし兄 Yoshi @aminfield]

Autoantibodies against Cytokines — From Infection to Inflammation | New England Journal of Medicine https://t.co/9x3cl29r0K